# EDGAR Filing Document

**Accession Number:** 0002008861
**File Stem:** 0001104659-25-073018
**Filing Date:** 2025-8
**Character Count:** 85948
**Document Hash:** 29608180cf824383646039edd8fc7bf8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-073018.hdr.sgml**: 20250801

**ACCESSION NUMBER**: 0001104659-25-073018

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20250731

**ITEM INFORMATION**: Completion of Acquisition or Disposition of Assets

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Changes in Control of Registrant

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250801

**DATE AS OF CHANGE**: 20250801

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Endo LP
- **CENTRAL INDEX KEY:** 0002008861
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 301390281
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-280767
- **FILM NUMBER:** 251175230

**BUSINESS ADDRESS:**
- **STREET 1:** 9 GREAT VALLEY PARKWAY
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** (484) 216-0000

**MAIL ADDRESS:**
- **STREET 1:** 9 GREAT VALLEY PARKWAY
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Endo, Inc.
- **DATE OF NAME CHANGE:** 20240119

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**

**of the Securities Exchange Act of 1934**

July 31, 2025

Date of Report (Date of Earliest Event Reported)

**Endo LP**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **333-280767** | **30-1390281** |
| **(State or other jurisdiction<br> of incorporation)** | **(Commission<br> File Number)** | **(IRS Employer<br> Identification No.)** |

---

**9 Great Valley Parkway, Malvern, Pennsylvania 19355**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: +1 (484) 216-0000**

**Endo, Inc.**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

◻ Emerging growth company <br> ◻ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Introduction**

Transaction Agreement

On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended on April 23, 2025, the "<u>Transaction Agreement</u>"), by and among Endo, Inc., a Delaware corporation (which has been converted into Endo LP, a Delaware limited partnership, the "<u>Company</u>" or "<u>Endo</u>"), Mallinckrodt plc, an Irish public limited company ("<u>Mallinckrodt</u>"), and Salvare Merger Sub LLC, a Delaware limited liability company and a wholly owned subsidiary of the Mallinckrodt ("<u>Merger Sub</u>"), Mallinckrodt acquired Endo by means of the merger of Merger Sub with and into the Company (such merger, the "<u>Merger</u>" and, together with other transactions contemplated by the Transaction Agreement, the "<u>Transactions</u>"), with the Company surviving the merger as a wholly owned subsidiary of Mallinckrodt.

*Effect on Capital Stock*

On July 31, 2025, pursuant to the Transaction Agreement, at the Effective Time of the business combination (the "<u>Effective Time</u>"), each share of common stock, par value $0.001 per share, of the Company ("<u>Company Common Stock</u>") that was issued and outstanding as of immediately prior to the Effective Time, other than shares of Company Common Stock owned by the Company, any Company subsidiary, Mallinckrodt, Merger Sub or any of their respective subsidiaries, was cancelled and converted into the right to receive (i) 0.2575 of an ordinary share of Mallinckrodt (the "<u>Mallinckrodt Ordinary Shares</u>") (such number of Mallinckrodt Ordinary Shares, the "<u>Per Share Stock Consideration</u>") and approximately $1.31 in cash (the "<u>Per Share Cash Consideration</u>" and together with the Per Share Stock Consideration, the "<u>Transaction Consideration</u>"). , without interest and subject to applicable withholding. Former holders of Endo common stock will receive cash in lieu of any fractional Mallinckrodt Ordinary Shares they would otherwise have been entitled to receive.

Following the Merger, on August 1, 2025, the Company converted into Endo LP, a Delaware limited partnership (the "<u>Conversion</u>"). In the Conversion, all of the Company Common Stock issued and outstanding prior to the Conversion was converted into one hundred percent (100%) of the partnership interest of Endo LP.

*Treatment of Equity Awards*

Pursuant to the Transaction Agreement, at the Effective Time:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) each outstanding restricted stock unit award in respect of Endo common stock that was subject only to time-based vesting requirements (an "<u>Endo RSU Award</u>") and that was held by an employee of Endo or a subsidiary of Endo, was assumed by Mallinckrodt and converted into a restricted stock unit award in respect of a number of Mallinckrodt Ordinary Shares (a "<u>Mallinckrodt RSU Award</u>") equal to (i) the total number of shares of Endo common stock underlying such Endo RSU Award as of immediately prior to the Effective Time multiplied by (ii) the sum of (x) the Per Share Stock Consideration plus (y) the quotient obtained by dividing the Per Share Cash Consideration by a measure of the price per share of Mallinckrodt Ordinary Shares as specified in the Transaction Agreement (referred to as the "<u>Mallinckrodt Per Share Price</u>"). Each Mallinckrodt RSU Award will continue to have, and will continue to be subject to, the same terms and conditions (including vesting schedules) that applied to the corresponding Endo RSU Award as of immediately prior to the Effective Time, except that such Mallinckrodt RSU Award will be accelerated upon certain terminations of employment, as described below;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) each outstanding Endo RSU Award that was held by a non-employee director of Endo became fully vested and all rights in respect of such Endo RSU Award were canceled and automatically converted into the right of the holder to receive an amount in cash equal to the product of (i) the number of shares of Endo common stock underlying such Endo RSU Award multiplied by (ii) the sum of (x) the Mallinckrodt Per Share Price multiplied by the Per Share Stock Consideration plus (y) the Per Share Cash Consideration; provided, however, that for this purpose, Mr. Hirsch will be treated as a non-employee director;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) each outstanding restricted stock unit award in respect of Endo common stock that was subject, in whole or in part, to performance-based vesting conditions (an "<u>Endo PSU Award</u>") was assumed by Mallinckrodt and converted into a Mallinckrodt RSU Award in respect of a number of Mallinckrodt Ordinary Shares equal to the product of (i) the total number of shares of Endo common stock underlying such Endo PSU Award as of immediately prior to the Effective Time (assuming performance goals are achieved at the target level), multiplied by (ii) the sum of (x) the Per Share Stock Consideration plus (y) the quotient obtained by dividing the Per Share Cash Consideration by the Mallinckrodt Per Share Price. Such Mallinckrodt RSU Award shall otherwise be subject to the same terms and conditions (including vesting) as applied to the corresponding Endo PSU Award as of immediately prior to the Effective Time, except that such Mallinckrodt RSU Award will be accelerated upon certain terminations of employment, as described below; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) each outstanding long-term cash award granted by Endo which was subject to time-based vesting requirements and/or performance-based vesting requirements (an "<u>Endo Cash LTI Award</u>") was assumed by Mallinckrodt and converted into a long-term cash award granted by Mallinckrodt (a "<u>Mallinckrodt Cash LTI Award</u>"). Each such Mallinckrodt Cash LTI Award will be subject to the same terms and conditions (including vesting) as applied to the corresponding Endo Cash LTI Award as of immediately prior to the Effective Time; provided that any performance goals that applied to the Endo Cash LTI Award were assumed to have been earned at the target level as of immediately prior to the Effective Time and such Mallinckrodt Cash LTI Award will be accelerated upon certain terminations of employment, as described below. The Mallinckrodt RSU Awards and Mallinckrodt Cash LTI Awards issued in replacement of Endo RSU Awards, Endo PSU Awards and Endo Cash LTI Awards, as applicable, are referred to as "<u>Replacement Awards</u>."

If the holder of any Replacement Award experiences a termination of employment (i) by Mallinckrodt or any subsidiary of Mallinckrodt without "cause" (as defined in the Endo 2024 Stock Incentive Plan) or (ii) by the holder for "good reason" (to the extent such holder has an employment agreement that provides for severance benefits upon a resignation for "good reason," and in such case as defined in such employment agreement), in either case, during the 24-month period following the Effective Time, such Replacement Award will become fully vested at the time of such termination.

The foregoing description of the Transaction Agreement and the transactions contemplated thereby, including the Merger, does not purport to be complete, and is subject to and qualified in its entirety by reference to the full text of the Transaction Agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K and incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 2.01** | **Completion of Acquisition or Disposition of Assets.** |

---

The information set forth in the Introduction of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.

---

| | |
|:---|:---|
| **Item 3.01.** | **Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.** |

---

The information set forth in the Introduction and Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.01.

The Company notified the OTCQX Best Market ("<u>OTCQX</u>") on July 31, 2025 of the consummation of the Transaction. In connection with the consummation of the Transaction, the Company requested that the OTCQX suspend trading of Company Common Stock on the OTCQX and remove Company Common Stock from listing on the OTCQX, in each case, prior to the opening of the market on August 1, 2025.

The Company will file a Form 15 with the Securities and Exchange Commission to suspend the Company's reporting obligations under Sections 13 and 15(d) of the Securities and Exchange Act of 1934, as amended.

---

| | |
|:---|:---|
| **Item 3.03.** | **Material Modification to Rights of Security Holders.** |

---

The information set forth in the Introduction, Item 2.01, Item 5.01, Item 5.02 and Item 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

At the Effective Time, each holder of Company Common Stock immediately prior to the Effective Time ceased to have any rights as a stockholder of the Company other than the right to receive the Transaction Consideration pursuant to the Transaction Agreement.

---

| | |
|:---|:---|
| **Item 5.01.** | **Changes in Control of Registrant.** |

---

The information set forth in the Introduction, Item 2.01, Item 3.01, Item 3.03, Item 5.02 and Item 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.

As a result of the Merger, a change in control of the Company occurred, and the Company is now a wholly owned subsidiary of Mallinckrodt.

---

| | |
|:---|:---|
| **Item 5.02.** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

The information set forth in the Introduction of this Current Report on Form 8-K is incorporated by reference into this Item 5.02.

As of immediately following the Effective Time, in accordance with the Transaction Agreement, each of Paul Herendeen, Paul Efron, Scott Hirsch, Sophia Langlois, Andy Pasternak and Marc Yoskowitz, comprising all of the members of the Company's board of directors, ceased serving as a member of the Company's board of directors and each committee thereof. As of immediately following the Effective Time, each of Matthew Peters and Mark Tyndall became a member of, and collectively comprise the sole members of, the Company's board of directors.

Each of Scott Hirsch, Mark T. Bradley, Matthew J. Maletta and James P. Tursi, M.D., who were officers of the Company as of immediately prior to the Effective Time, ceased to be an officer of the Company immediately following the Effective Time. In addition, effective as of immediately following the Effective Time, Matthew Peters was appointed to serve as the President and Treasurer of the Company.

Mallinckrodt recently approved its ordinary course independent valuation of the Mallinckrodt Ordinary Shares, which resulted in a per-share valuation that is greater than the per-share valuation implied by the cash-out amount that is payable to Endo's directors for their Endo RSU Awards under the formula in the Transaction Agreement. To ensure more consistent treatment of Endo and Mallinckrodt directors, the Company's board of directors approved a payment to directors in respect of their Endo RSU Awards based on the value implied by Mallinckrodt's most recent independent valuation, which resulted in an aggregate incremental payment to Endo's directors of approximately $645,000.

Prior to the Effective Time, Mr. Tursi, who served as the Company's Executive Vice President, Global Research and Development, entered into a transition and separation agreement (the "<u>Separation Agreement</u>"), dated July 30, 2025, pursuant to which Mr. Tursi would be terminated on the day that is 60 days after the Effective Time and would be entitled to receive the compensation and benefits described in the Separation Agreement, subject to his compliance with the terms and conditions of the Separation Agreement.

On July 29, 2025, Endo entered into a Noncompetition and Consulting Agreement (the "<u>Consulting Agreement</u>") with Mr. Hirsch, which amended the Employment Agreement between Endo and Mr. Hirsch dated August 26, 2024 (as amended on January 6, 2025, the "<u>Employment Agreement</u>") and modified the Transition Letter entered into between Endo and Mr. Hirsch on March 13, 2025 in connection with the signing of the Transaction Agreement. Pursuant to the terms of the Consulting Agreement, Mr. Hirsch will no longer serve as the interim Chief Executive Officer of the Company, but will continue to be employed as a senior advisor to the Company in a full-time capacity through the date that is 60 days after the later of the Merger Effective Time or August 15, 2025 (the "<u>Transition Period</u>"). During the Transition Period, Mr. Hirsch will continue to receive the same compensation and benefits as provided for under his Employment Agreement, which includes a monthly base salary of $750,000. Following the Transition Period, Mr. Hirsch's employment will terminate, and the Company will engage Mr. Hirsch as a consultant to provide transitional services for a period of six months following the Transition Period.

Pursuant to the terms of the Consulting Agreement, Mr. Hirsch will receive (i) $750,000 per month for a period of 12 months following the Transition Period, for a total of $9,000,000, and (ii) contingent upon his making a valid election to continue group health benefits in accordance with COBRA, payment of the full premium under COBRA for him and his dependents for 12 months following the end of the Transition Period, subject to his signing and not revoking a release of claims against the Company and his compliance with certain non-competition obligations commencing as of the Effective Time and continuing for 12 months after the end of the Transition Period.

In light of their additional efforts in connection with the completion of the Transaction, the Company's board of directors (including the disinterested members of the board) approved transaction bonuses for certain of Endo's non-employee directors as follows: Mr. Herendeen, $100,000; Ms. Langlois, $100,000; Mr. Pasternak, $100,000; Mr. Yoskowitz, $250,000.

---

| | |
|:---|:---|
| **Item 5.03.** | **Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.** |

---

The information set forth in Item 2.01, Item 3.03, Item 5.01 and Item 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03.

Pursuant to the Transaction Agreement, at the Effective Time, the certificate of incorporation of the Company and the bylaws of the Company were amended and restated and, respectively, as so amended and restated, became the certificate of incorporation and bylaws of the Company until further changed or amended as provided therein or by applicable law. Copies of the Company's amended and restated certificate of incorporation and bylaws are attached as Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated by reference into this Item 5.03.

Following the Merger, on August 1, 2025, the Company effectuated the Conversion, and is governed by the terms of a certificate of limited partnership and limited partnership agreement, which are attached as Exhibits 3.2 and 3.3 to this Current Report on Form 8-K and incorporated by reference into this Item 5.03.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) *Exhibits*

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| [2.1\*](https://www.sec.gov/Archives/edgar/data/2008861/000119312525054905/d934152dex21.htm) | [Transaction Agreement, dated as of March 13, 2025, by and among Endo, Inc., Mallinckrodt plc and Salvare Merger Sub LLC (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Company on March 14, 2025).](https://www.sec.gov/Archives/edgar/data/2008861/000119312525054905/d934152dex21.htm) |
| [2.2](https://www.sec.gov/Archives/edgar/data/2008861/000110465925047383/tm2514691-1_defm14a.htm#tANNC) | [Amendment to the Transaction Agreement, dated as of April 23, 2025, by and among Mallinckrodt plc, Salvare Merger Sub LLC and Endo, Inc. (incorporated by reference to Annex C to the Proxy Statement filed by the Company with the Securities and Exchange Commission on May 12, 2025)](https://www.sec.gov/Archives/edgar/data/2008861/000110465925047383/tm2514691-1_defm14a.htm#tANNC) |
| [3.1](tm2522236d1_ex3-1.htm) | [Amended and Restated Certificate of Incorporation of Endo, Inc., dated July 31, 2025.](tm2522236d1_ex3-1.htm) |
| [3.2](tm2522236d1_ex3-2.htm) | [Amended and Restated Bylaws of Endo, Inc., dated July 31, 2025.](tm2522236d1_ex3-2.htm) |
| [3.3](tm2522236d1_ex3-3.htm) | [Certificate of Limited Partnership of Endo LP, dated July 29, 2025.](tm2522236d1_ex3-3.htm) |
| [3.4](tm2522236d1_ex3-4.htm) | [Limited Partnership Agreement of Endo LP, dated August 1, 2025.](tm2522236d1_ex3-4.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**\***Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K promulgated by the SEC. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ENDO LP** | **ENDO LP** |
|  | By: ELP 2025 GP Limited | By: ELP 2025 GP Limited |
|  | Its: General Partner | Its: General Partner |
| Date: August 1, 2025 | By: | /s/ Mark Tyndall |
|  | Name: | Mark Tyndall |
|  | Title: | Authorised Signatory |

---

## Exhibit 3.1

**Exhibit 3.1**

**AMENDED AND RESTATED CERTIFICATE OF INCORPORATION**

**OF**

**ENDO, INC.**

**July 31, 2025**

FIRST: The name of the corporation (which is hereinafter referred to as the "<u>Corporation</u>") is Endo, Inc.

SECOND: The address of the Corporation's registered office in the State of Delaware is The Corporation Trust Center, 1209 Orange Street in the City of Wilmington, County of New Castle, Delaware 19801. The name of the Corporation's registered agent at such address is The Corporation Trust Company.

THIRD: The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware (the "<u>DGCL</u>").

FOURTH: The total number of shares of all classes of capital stock which the Corporation shall have the authority to issue is 1000 shares of common stock with a par value of $0.01 per share.

FIFTH: In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, alter or repeal the Bylaws of the Corporation, subject to any specific limitation on such power contained in any Bylaws adopted by the stockholders. Elections of directors need not be by written ballot unless the Bylaws of the Corporation so provide.

SIXTH: To the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, no director or officer of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, as applicable. All references in this SIXTH ARTICLE to a director shall also be deemed to refer to such other person or persons, if any, who, pursuant to a provision of this Amended and Restated Certificate of Incorporation in accordance with Section 141(a) of the DGCL, exercise or perform any of the powers or duties otherwise conferred or imposed upon the board of directors by the DGCL. All references in this SIXTH ARTICLE to an officer shall mean only a person who at the time of an act or omission as to which liability is asserted is deemed to have consented to service by the delivery of process to the registered agent of the Corporation pursuant to Section 3l14(b) of Title 10 of the Delaware Code (for purposes of this sentence only, treating residents of Delaware as if they were nonresidents to apply Section 3l14(b) of Title 10 of the Delaware Code to this sentence). Any amendment, repeal or elimination of this SIXTH ARTICLE, or the adoption of any provision of this Amended and Restated Certificate of Incorporation inconsistent with this SIXTH ARTICLE, shall not affect its application with respect to an act or omission by a director or officer occurring before such amendment, adoption, repeal or elimination.

SEVENTH: Subject to the last sentence of the SIXTH ARTICLE, the Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon the stockholders herein are granted subject to this reservation.

## Exhibit 3.2

**Exhibit 3.2**

**AMENDED AND RESTATED BYLAWS**

**OF**

**ENDO, INC.**

**Article I.** **<br> OFFICES**

**Section 1.** **<u>Registered Office</u>**. The registered office of Endo, Inc. (the "<u>Corporation</u>") in the State of Delaware shall be located at such location as stated in the Certificate of Incorporation of the Corporation, which may be changed from time to time.

**Section 2.** **<u>Special Meetings</u>**. The Corporation may also have offices at such other places, both within and without the State of Delaware as the board of directors (the "<u>Board of Directors</u>") may from time to time determine or as the business of the Corporation may require.

**Article II.** **<br> MEETING OF STOCKHOLDERS**

**Section 1.** **<u>Annual Meeting</u>**. The annual meeting of stockholders shall be held on such date and at such time as may be chosen by the Board of Directors. Any other proper business may be transacted at the annual meeting of stockholders.

**Section 2.** **<u>Special Meetings</u>**. Special meetings of the stockholders may be called for any purpose and may be held at such time and place, within or without the State of Delaware, as shall be stated in a notice of meeting or in a duly executed waiver of notice thereof. Such meetings may be called at any time by the Board of Directors or the President and shall be called by the President upon the written request of holders of shares entitled to cast not less than a majority of the votes at the meeting, such written request shall state the purpose or purposes of the meeting and shall be delivered to the President.

**Section 3.** **<u>Place of Meeting</u>**. The Board of Directors may designate any place, either within or without the State of Delaware, as the place of meeting for any annual meeting or for any special meeting called by the Board of Directors. A waiver of notice signed by all stockholders may designate any place, either within or without the State of Delaware, as the place for the holding of such meeting.

**Section 4.** **<u>Notice of Meetings</u>**. Whenever stockholders are required or permitted to take any action at a meeting, a written notice of the meeting shall be given which shall state the place, date and hour of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. Unless otherwise required by law, the written notice of any meeting shall be given not less than ten nor more than sixty days before the date of the meeting to each stockholder entitled to vote at such meeting.

**Section 5.** **<u>Meeting of All Stockholders</u>**. If all of the stockholders shall meet at any time and place, either within or without the State of Delaware, and shall consent to the holding of a meeting at such time and place, such meeting shall be valid without call or notice, and any corporate action may be taken at such meeting.

**Section 6.** **<u>Adjournments</u>**. Any meeting of the stockholders may be adjourned from time to time to reconvene at the same or some other place, and notice need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Corporation may transact any business that might have been transacted at the original meeting. If the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.

**Section 7.** **<u>Stockholder List</u>**. The officer of the Corporation who has charge of the stock ledger of the Corporation shall prepare and make, at least ten days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten days prior to the meeting either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder of the Corporation who is present.

**Section 8.** **<u>Quorum</u>**. The holders of a majority of the outstanding shares of capital stock, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders, except as otherwise provided by statute or by the Certificate of Incorporation. If a quorum is not present, the holders of majority of the shares present in person or represented by proxy at the meeting, and entitled to vote at the meeting, may adjourn the meeting to another time and/or place.

**Section 9.** **<u>Proxies</u>**. At all meetings of stockholders, a stockholder may vote by proxy executed in writing by the stockholder or by his or her duly authorized attorney-in-fact. Such proxy shall be filed with the Secretary of the Corporation before or at the time of the meeting. No proxy shall be valid after eleven months from the date of its execution, unless otherwise provided in the proxy.

**Section 10.** **<u>Voting of Shares</u>**. Unless otherwise provided in the Certificate of Incorporation, each outstanding share, regardless of class, shall be entitled to one vote in person or by proxy upon each matter submitted to a vote of the stockholders.

**Section 11.** **<u>Action by Written Consent</u>**. Any action required to be taken at a meeting of the stockholders, or any other action which may be taken at a meeting of the stockholders, may be taken without a meeting and without a vote, if a consent in writing, setting forth the action so taken, shall be signed (i) by the holders of outstanding shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voting, or (ii) by all of the stockholders entitled to vote with respect to the subject matter thereof. If such consent is signed by less than all of the stockholders entitled to vote, then such consent shall become effective only if at least five days prior to the execution of the consent a notice in writing is delivered to all the stockholders entitled to vote with respect to the subject matter thereof and, after the effective date of the consent, prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be delivered in writing to those stockholders who have not consented in writing.

**Article III.** **<br> DIRECTORS**

**Section 1.** **<u>Number and Tenure</u>**. The Board of Directors shall consist of not less than one nor more than ten members, the exact number of which shall initially be fixed from time to time by the Board of Directors. Except as provided in Section 2 of this Article III, directors shall be elected by a plurality of the votes cast at the annual meetings of stockholders and each director so elected shall hold office until the next annual meeting of stockholders and until such director's successor is duly elected and qualified, or until such director's earlier death, resignation or removal. Any director may resign at any time upon written notice to the Corporation. Directors need not be stockholders.

**Section 2.** **<u>Vacancies</u>**. Unless otherwise required by law or the Certificate of Incorporation, vacancies arising through death, resignation, removal, an increase in the number of directors or otherwise may be filled only by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal.

**Section 3.** **<u>Duties and Powers</u>**. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors, which may exercise all such powers of the Corporation and do all such lawful acts and things as are not by statute or by the Certificate of Incorporation or by these bylaws required to be exercised or done by the stockholders.

**Section 4.** **<u>Meetings</u>**. The Board of Directors may hold meetings, both regular and special, either within or without the State of Delaware. Regular meetings of the Board of Directors may be held without notice at such time and at such place as may from time to time be determined by the Board of Directors. Special meetings of the Board of Directors may be called by the Chairman, if there be one, the President, or by any director. Notice thereof stating the place, date and hour of the meeting shall be given to each director either by mail not less than forty-eight hours before the date of the meeting, by telephone or email on twenty-four hours' notice, or on such shorter notice as the person or persons calling such meeting may deem necessary or appropriate in the circumstances.

**Section 5.** **<u>Quorum</u>**. Except as otherwise required by law or the Certificate of Incorporation, at all meetings of the Board of Directors, a majority of the entire Board of Directors shall constitute a quorum for the transaction of business and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board of Directors. If a quorum shall not be present at any meeting of the Board of Directors, the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting of the time and place of the adjourned meeting, until a quorum shall be present.

**Section 6.** **<u>Actions by Written Consent</u>**. Unless otherwise provided in the Certificate of Incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all the members of the Board of Directors or committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board of Directors or committee.

**Section 7.** **<u>Meetings by Means of Conference Telephone</u>**. Unless otherwise provided in the Certificate of Incorporation, members of the Board of Directors, or any committee thereof, may participate in a meeting of the Board of Directors or such committee by means of a conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this Section 7 shall constitute presence in person at such meeting.

**Section 8.** **<u>Presumption of Assent</u>**. A director of the Corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be conclusively presumed to have assented to the action taken unless his or her dissent shall be entered in the minutes of the meeting or unless he or she shall file his or her written dissent to such action with the person acting as the Secretary of the meeting before the adjournment thereof or shall forward such dissent by registered or certified mail to the Secretary of the Corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to a director who voted in favor of such action.

**Section 9.** **<u>Removal of Directors</u>**. One or more of the directors of the Corporation may be removed, with or without cause, at a meeting of stockholders by the affirmative vote of the holders of a majority of the outstanding shares then entitled to vote at an election of directors except as otherwise provided by law.

**Section 10.** **<u>Committees</u>**. The Board of Directors may create one or more committees of the Board of Directors and appoint directors to serve on the committee or committees. Each committee shall have two or more members, who serve at the pleasure of the Board of Directors. Each committee may exercise the authority of the Board of Directors except as otherwise provided by law.

**Article IV.** **<br> OFFICERS**

**Section 1.** **<u>Number</u>**. The officers of the Corporation shall be chosen by the Board of Directors and may consist of a President, one or more Vice-Presidents, a Secretary, a Treasurer, and one or more Assistant Secretaries and Assistant Treasurers and such other officers as may be designated by the Board of Directors. Any number of offices may be held by the same person.

**Section 2.** **<u>Election and Term of Office</u>**. The officers of the Corporation shall be elected annually by the Board of Directors at the regular meeting of the Board of Directors held after each annual meeting of stockholders. If the election of officers shall not be held at such meeting, such election shall be held as soon thereafter as may be convenient. Vacancies may be filled or new offices created and filled at any meeting of the Board of Directors. Each officer shall hold office until his or her successor shall have been duly elected and shall have qualified or until his or her death or until he or she shall resign or shall have been removed in the manner hereinafter provided. Election or appointment of an officer or agent shall not of itself create contract rights.

**Section 3.** **<u>Compensation</u>**. The salaries of all officers of the Corporation shall be fixed from time to time by the Board of Directors and no officer shall be prevented from receiving such salary by reason of the fact that he or she is also a director of the Corporation.

**Section 4.** **<u>Resignations</u>**. Any officer may resign at any time by giving notice to the Board of Directors or to the President or Secretary. A resignation of an officer need not be accepted in order to be effective.

**Section 5.** **<u>Removal</u>**. Any officer or agent elected or appointed by the Board of Directors may be removed by the Board of Directors whenever in its judgment the best interests of the Corporation would be served thereby, but such removal shall be without prejudice to the contract rights, if any, of the person so removed.

**Section 6.** **<u>Vacancies</u>**. A vacancy in any office because of death, resignation, removal, disqualification or otherwise, may be filled by the Board of Directors for the unexpired portion of the term.

**Section 7.** **<u>Duties of Officers</u>**. The duties and powers of the officers shall be as follows:

<u>President</u>

The President shall be the principal executive officer of the Corporation and shall be responsible for the administration and operation of the business and affairs of the Corporation. He or she shall preside at all meetings of the stockholders and the Board of Directors. He or she may sign with the Secretary, or any other proper officer of the Corporation thereunto authorized by the Board of Directors, any deeds, mortgages, bonds, contracts, or other instruments which the Board of Directors has authorized to be executed, except in cases where the signing and execution thereof shall be expressly delegated by the Board of Directors or by these bylaws to some other officer or agent of the Corporation, or shall be required by law to be otherwise signed or executed, and in general shall perform all duties incident to the office of president and such other duties as may be prescribed by the Board of Directors from time to time.

<u>Vice-Presidents</u>

The Vice-President, if there shall be one, or if there shall be more than one, the Vice-Presidents in the order determined by the Board of Directors (or if there be no such determination, then in the order of their election), shall, in the absence, disability or refusal to act of the President, perform the duties of the President, and when so acting, shall have all the power of and be subject to all the restrictions upon the President.

<u>Secretary</u>

The Secretary shall: (a) keep the minutes of the meetings of the stockholders, the Board of Directors and committees thereof in one or more books provided for that purpose; (b) see that all notices are duly given in accordance with the provisions of these bylaws or as required by law; (c) be custodian of the corporate records and of the seal of the Corporation and see that the seal of the Corporation is affixed to all documents, the execution of which on behalf of the Corporation under its seal is duly authorized in accordance with the provisions of these bylaws; (d) keep a register of the post-office address of each stockholder, which shall be furnished to the Secretary by such stockholder; (e) have general charge of the stock transfer books of the Corporation; and (f) generally perform all duties incident to the office of Secretary and such other duties as from time to time may be assigned to him or her by the President or by the Board of Directors.

<u>Treasurer</u>

If required by the Board of Directors, the Treasurer shall give a bond for the faithful discharge of the Treasurer's duties in such sum and with such surety or sureties as the Board of Directors shall determine. The Treasurer shall: (a) have the charge and custody of and be responsible for all funds and securities of the Corporation; (b) receive and give receipts for moneys due and payable to the Corporation from any source whatsoever, and deposit all such moneys not otherwise employed in the name of the Corporation in such bank, savings and loan association, trust company or other depositories as shall be selected in accordance with the provisions of Article IV of these bylaws; and (c) in general perform all the duties incident to the office of Treasurer and such other duties as from time to time may be assigned to him or her by the President or the Board of Directors.

<u>Assistant Secretaries and Assistant Treasurers</u>

The Assistant Treasurers shall respectively, if required by the Board of Directors, give bonds for the faithful discharge of their duties in such sums and with such sureties as the Board of Directors shall determine. The Assistant Treasurers and Assistant Secretaries, in general, shall perform such duties as shall be assigned to them from time to time by the Treasurer or the Secretary, respectively, or by the President or the Board of Directors.

**Article V.** **<br> CONTRACTS, LOANS, CHECKS AND DEPOSITS**

**Section 1.** **<u>Contracts</u>**. The Board of Directors may authorize any officer or officers, agent or agents, to enter into any contract or execute and deliver any instrument in the name of and on behalf of the Corporation, and such authority may be general or confined to specific instances.

**Section 2.** **<u>Loans</u>**. No loans shall be contracted on behalf of the Corporation and no evidences of indebtedness shall be issued in its name unless authorized by a resolution of the Board of Directors. Such authority may be general or confined to specific instances.

**Section 3.** **<u>Deposits</u>**. All funds of the Corporation not otherwise employed shall be deposited from time to time to the credit of the Corporation in such bank, savings and loan association, trust company or other depositories as the Board of Directors may select.

**Article VI.** **<br> INDEMNIFICATION**

**Section 1.** **<u>Right to Indemnification</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) Each person who was or is a party or is threatened to be made a party to, or was or is otherwise involved
in, any action, suit, arbitration, alternative dispute resolution mechanism, investigation, inquiry, judicial, administrative or legislative
hearing, or any other threatened, pending or completed proceeding, whether brought by or in the right of the Corporation or otherwise,
including any and all appeals, whether of a civil, criminal, administrative, legislative, investigative or other nature (hereinafter a
 " <u>Proceeding</u> "), by reason of the fact that he or she is or was a director or an officer of the Corporation or while
a director or an officer of the Corporation is or was serving at the request of the Corporation as a director, officer, employee, agent
or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an
employee benefit plan (hereinafter an " <u>Indemnitee</u> "), or by reason of anything done or not done by him or her in any
such capacity, shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists
or may hereafter be amended, against all expense, liability and loss (including attorneys' fees, judgments, fines, the Employee
Retirement Income Security Act of 1974 (ERISA) excise taxes, penalties and amounts paid in settlement by or on behalf of the Indemnitee)
actually and reasonably incurred by such Indemnitee in connection therewith, all on the terms and conditions set forth in these bylaws; <u>provided</u>, <u>however</u>,
that, except as otherwise required by law or provided in Section 4 of this Article VI with respect to
suits to enforce rights under this Article VI, the Corporation shall indemnify any such Indemnitee in connection with a Proceeding,
or part thereof, voluntarily initiated by such Indemnitee (including claims and counterclaims, whether such counterclaims are asserted
by such Indemnitee or the Corporation in a Proceeding initiated by such Indemnitee) only if such Proceeding, or part thereof, was authorized
or ratified by the Board of Directors or the Board of Directors otherwise determines that indemnification or advancement of expenses is
appropriate.

&nbsp;&nbsp;&nbsp;&nbsp;(b) To receive indemnification under this Article VI, an Indemnitee shall submit a written request
to the Secretary (or other officer designated by the Board of Directors) of the Corporation. Such request shall include documentation
or information that is necessary to determine the entitlement of the Indemnitee to indemnification and that is reasonably available to
the Indemnitee. Upon receipt by the Secretary (or other officer designated by the Board of Directors) of the Corporation of such a written
request, unless indemnification is required by Section 3 of this Article VI , the entitlement of the Indemnitee
to indemnification shall be determined by the following person or persons who shall be empowered to make such determination, as selected
by the Board of Directors (except with respect to <u>clause (v)</u> of this Section 1(b)): (i) the Board
of Directors by a majority vote of the directors who are not parties to such Proceeding, whether or not such majority constitutes a quorum;
(ii) a committee of such directors designated by a majority vote of such directors, whether or not such majority constitutes a quorum;
(iii) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion to the Board
of Directors, a copy of which shall be delivered to the Indemnitee; (iv) the stockholders of the Corporation; or (v) in the
event that a change of control (as defined below) has occurred, by independent legal counsel in a written opinion to the Board of Directors,
a copy of which shall be delivered to the Indemnitee. The determination of entitlement to indemnification shall be made and, unless a
contrary determination is made, such indemnification shall be paid in full by the Corporation not later than 60 days after receipt by
the Secretary (or other officer designated by the Board of Directors) of the Corporation of a written request for indemnification. For
purposes of this Section 1(b)  ***,*** a " <u>change of control</u> " will be deemed to have occurred if, with
respect to any particular 24-month period, the individuals who, at the beginning of such 24-month period, constituted
the Board of Directors (the " <u>incumbent board</u> "), cease for any reason to constitute at least a majority of the Board
of Directors; <u>provided</u>, <u>however</u>, that any individual becoming a director subsequent to the beginning of such 24-month period
whose election, or nomination for election by the stockholders of the Corporation, was approved by a vote of at least a majority of the
directors then comprising the incumbent board shall be considered as though such individual were a member of the incumbent board, but
excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election
contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on
behalf of a person other than the Board of Directors.

&nbsp;&nbsp;&nbsp;&nbsp;(c) Any reference to an officer of the Corporation in this Article VI shall be deemed to
refer exclusively to the President, Vice-Presidents, Secretary, Treasurer, Assistant Secretaries and Assistant Treasurers and any
officer of the Corporation appointed by the Board of Directors pursuant to Section 1 of Article IV or otherwise
specifically appointed as "officer" for purposes of these bylaws, and any reference to an officer of any other enterprise
shall be deemed to refer exclusively to an officer appointed by the board of directors or equivalent governing body of such other enterprise
pursuant to the certificate of incorporation and bylaws (or equivalent organizational documents) of such other enterprise. The fact that
any person who is or was an employee of the Corporation or an employee of any other enterprise has been given or has used the title of
 "Vice President" or any other title that could be construed to suggest or imply that such person is or may be an officer of
the Corporation or of such other enterprise shall not, by itself, result in such person being constituted as, or being deemed to be, an
officer of the Corporation or of such other enterprise for purposes of this Article VI.

**Section 2.** **<u>Right to Advancement of Expenses</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) In addition to the right to indemnification conferred in Section 1 of this Article VI,
an Indemnitee shall, to the fullest extent permitted by law, also have the right to be paid by the Corporation the expenses (including
attorneys' fees) incurred in defending any Proceeding in advance of its final disposition (hereinafter an " <u>advancement of expenses</u> "); <u>provided</u>, <u>however</u>, that an advancement of expenses shall be made only upon delivery to
the Corporation of an undertaking (hereinafter an " <u>undertaking</u> "), by or on behalf of such Indemnitee, to repay all
amounts so advanced if it shall ultimately be determined by final judicial decision of a court of competent jurisdiction from which there
is no further right to appeal (hereinafter a " <u>Final Adjudication</u> ") that such Indemnitee is not entitled to be indemnified
for such expenses under this Article VI or otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;(b) To receive an advancement of expenses under this Section 2, an Indemnitee shall submit
a written request to the Secretary of the Corporation (or other officer designated by the Board of Directors). Such request shall reasonably
evidence the expenses incurred by the Indemnitee and shall include or be accompanied by the undertaking required by Section 2(a) of
this Article VI. <u> </u> Each such advancement of expenses shall be made within 20 days after the receipt by the Secretary of
the Corporation (or other officer designated by the Board of directors) of a written request for advancement of expenses.

&nbsp;&nbsp;&nbsp;&nbsp;(c) Notwithstanding the foregoing Section 2(a) of this Article VI, the Corporation
shall not make or continue to make advancements of expenses to an Indemnitee pursuant to 2(a) of this Article VI (except
in connection with any Proceeding initiated against such Indemnitee by reason of the fact that he or she is a current director of the
Corporation, in which event this Section 2(c) of this Article VI shall not apply) if a determination is reasonably
made that the facts known at the time such determination is made demonstrate clearly and convincingly that the Indemnitee acted in bad
faith or in a manner that the Indemnitee did not reasonably believe to be in or not opposed to the best interests of the Corporation,
or, with respect to any criminal proceeding, that the Indemnitee had reasonable cause to believe his or her conduct was unlawful. Such
determination shall be made: (i) by the Board of Directors by a majority vote of directors who are not parties to such Proceeding,
whether or not such majority constitutes a quorum; (ii) by a committee of such directors designated by a majority vote of such directors,
whether or not such majority constitutes a quorum; or (iii) if there are no such directors, or if such directors so direct, by independent
legal counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to the Indemnitee.

**Section 3.** **<u>Indemnification for Successful Defense</u>**. Notwithstanding anything to the contrary, to the extent that an Indemnitee has been successful on the merits or otherwise in defense of any Proceeding (or in defense of any claim, issue or matter therein), such Indemnitee shall be indemnified under this Section 3 against expenses (including attorneys' fees) actually and reasonably incurred in connection with such defense. Indemnification under this Section 3 shall not be subject to satisfaction of a standard of conduct, and the Corporation may not assert the failure to satisfy a standard of conduct as a basis to deny indemnification or recover amounts advanced, including in a suit brought pursuant to Section 4 of this Article VI (notwithstanding anything to the contrary therein).

**Section 4.** **<u>Right of Indemnitee to Bring Suit</u>**. In the event that a determination is made that the Indemnitee is not entitled to indemnification or if payment is not timely made following a determination of entitlement to indemnification pursuant to Section 1(b) of this Article VI, if a request for indemnification under Section 3 of this Article VI is not paid in full by the Corporation within 60 days after a written request has been received by the Secretary of the Corporation, or if an advancement of expenses is not timely made under Section 2(b) of this Article VI, the Indemnitee may at any time thereafter bring suit against the Corporation in a court of competent jurisdiction in the State of Delaware seeking an adjudication of entitlement to such indemnification or advancement of expenses. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall be entitled to be paid also the expense of prosecuting or defending such suit to the fullest extent permitted by law. In any suit brought by the Indemnitee to enforce a right to indemnification hereunder, it shall be a defense that the Indemnitee has not met any applicable standard of conduct for indemnification set forth in Section 145(a) or Section 145(b) of the DGCL. In connection with any suit brought by an Indemnitee for advancement (except in connection with any Proceeding initiated against such Indemnitee by reason of the fact that he or she is a current director of the Corporation), the Corporation shall be entitled to raise a defense as to any suit clear and convincing evidence that the Indemnitee acted in bad faith or in a manner that the Indemnitee did not reasonably believe to be in or not opposed to the best interests of the Corporation, or with respect to any criminal proceeding, that such Indemnitee had reasonable cause to believe that his or her conduct was unlawful. Further, in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a Final Adjudication that the Indemnitee has not met any applicable standard of conduct for indemnification set forth in Section 145(a) or Section 145(b) of the DGCL. Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met such applicable standard of conduct, nor an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) that the Indemnitee has not met such applicable standard of conduct, shall create a presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, be a defense to such suit. In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under applicable law, this Article VI or otherwise shall be on the Corporation.

**Section 5.** **<u>Non-Exclusivity of Rights</u>**. The rights to indemnification and to the advancement of expenses conferred in this Article VI shall not be exclusive of any other right which any person may have or hereafter acquire under any law, agreement, vote of stockholders or disinterested directors, provisions of a certificate of incorporation or bylaws, or otherwise.

**Section 6.** **<u>Insurance</u>**. The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the DGCL.

**Section 7.** **<u>Indemnification of Employees and Agents of the Corporation; Services at Subsidiaries</u>**. The Corporation may, to the extent and in the manner permitted by law, and to the extent authorized from time to time, grant rights to indemnification and to the advancement of expenses to any employee or agent of the Corporation. In addition, the Corporation may, to the extent and in the manner permitted by law, and to the extent authorized from time to time, grant rights to indemnification and to the advancement of expenses to individuals with respect to their service as a director, officer, employee or agent of subsidiaries of the Corporation.

**Section 8.** **<u>Nature of Rights</u>**. The rights conferred upon Indemnitees in this Article VI shall be contract rights and such rights shall continue as to an Indemnitee who has ceased to be a director or officer and shall inure to the benefit of the Indemnitee's heirs, executors and administrators. Any amendment, alteration or repeal of this Article VI that adversely affects any right of an Indemnitee or its successors shall be prospective only and shall not limit or eliminate any such right with respect to any Proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment, alteration or repeal.

**Section 9.** **<u>Settlement of Claims</u>**. Notwithstanding anything in this Article VI to the contrary, the Corporation shall not be liable to indemnify any Indemnitee under this Article VI for any amounts paid in settlement of any Proceeding effected without the Corporation's written consent, which consent shall not be unreasonably withheld.

**Section 10.** **<u>Subrogation</u>**. In the event of payment under this Article VI, the Corporation shall be subrogated to the extent of such payment to all of the rights of recovery of the Indemnitee (excluding insurance obtained on the Indemnitee's own behalf), and the Indemnitee shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable the Corporation effectively to bring suit to enforce such rights.

**Section 11.** **<u>Severability</u>**. If any provision or provisions of this Article VI shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law: (a) the validity, legality and enforceability of such provision in any other circumstance and of the remaining provisions of this Article VI (including, without limitation, all portions of any paragraph of this Article VI containing any such provision held to be invalid, illegal or unenforceable, that are not by themselves invalid, illegal or unenforceable) and the application of such provision to other persons or entities or circumstances shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Article VI (including, without limitation, all portions of any paragraph of this Article VI containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the intent of the parties that the Corporation provide protection to the Indemnitee to the fullest extent set forth in this Article VI.

**Article VII.**

**Section 1.** **<u>Certificates For Shares</u>**. The issued shares of the Corporation shall be represented by certificates or shall be uncertified shares. Certificates representing shares of the Corporation shall be in such form as may be determined by the Board of Directors. Such certificates shall be signed by the President or a Vice-President and by the Secretary or an Assistant Secretary. All certificates for shares shall be consecutively numbered or otherwise identified. The name of the person to whom the shares represented thereby are issued, with the number of shares and date of issue, shall be entered on the books of the Corporation. All certificates surrendered to the Corporation for transfer shall be cancelled and no new certificate shall be issued until the former certificate for a like number of shares shall have been surrendered and cancelled, except that in case of a lost, destroyed or mutilated certificate a new one may be issued therefor upon such terms and indemnity to the Corporation as the Board of Directors may prescribe.

**Section 2.** **<u>Transfer of Shares</u>**. Transfers of shares of the Corporation shall be made only on the books of the Corporation by the holder of record thereof or by his or her legal representative, who shall furnish proper evidence of authority to transfer, or by his or her attorney thereunto authorized by power of attorney duly executed and filed with the Secretary of the Corporation, and on surrender for cancellation of the certificate for such shares. The person in whose name shares stand on the books of the Corporation shall be deemed the owner thereof for all purposes as regards the Corporation.

**Article VIII.** **<br> VOTING OF SECURITIES**

The President shall have full authority, in the name and on behalf of the Corporation, to attend, act and vote at any meeting of security holders of any corporation in which the Corporation may hold securities, and at any such meeting shall possess and may exercise any and all rights and powers incident to the ownership of such securities and which, as the holder thereof, the Corporation might possess and exercise if personally present, and may exercise such power and authority through the execution of proxies or may delegate such power and authority to any other officer, agent or employee of the Corporation.

**Article IX.** **<br> FISCAL YEAR**

The fiscal year of the Corporation shall begin on the first day of January of each year and end on the last day of December of the same year, or shall extend for such other 12 consecutive months as the Board of Directors may designate..

**Article X.** **<br> WAIVER OF NOTICE**

Whenever any notice is required to be given under the provisions of these bylaws, the Certificate of Incorporation or the General Corporation Law of the State of Delaware, a waiver thereof in writing, signed by the person or persons entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice.

**Article XI.** **<br> AMENDMENTS**

These bylaws may be altered, amended or repealed and new bylaws may be adopted at any properly constituted meeting of the stockholders or Board of Directors by a majority vote of a quorum (as defined in these bylaws).

\*\*\*

## Exhibit 3.3

**Exhibit 3.3**

**CERTIFICATE OF LIMITED PARTNERSHIP**

**OF**

**ENDO LP**

The undersigned, desiring to form a limited partnership pursuant to the Delaware Revised Uniform Limited Partnership Act, 6 Delaware Code, Chapter 17, does hereby certify as follows:

1. The name of the limited partnership is Endo LP.

2. The address of the limited partnership's registered office in the
State of Delaware is Corporation Trust Center, 1209 Orange Street , Wilmington, County of New Castle, Delaware 19801. The name of
the Registered Agent at such address is The Corporation Trust Company.

3. The name and mailing address of the general partner is as follows:

ELP 2025 GP Limited

9 Great Valley Parkway

Malvern, PA 19355

4. This Certificate of Limited Partnership is to become effective
at 12:01 a.m. Eastern Time on August 1, 2025.

*[Remainder of page intentionally left blank. Signature page to follow.]*

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Limited Partnership as of the 29th day of July, 2025.

---

| | |
|:---|:---|
| ELP 2025 GP LIMITED, an Irish private company limited by shares | ELP 2025 GP LIMITED, an Irish private company limited by shares |
| as General Partner | as General Partner |
| By: | /s/ Alasdair John Fenlon |
| Name: | Alasdair John Fenlon |
| Title: | Authorised Officer |

---

## Exhibit 3.4

**Exhibit 3.4**

**LIMITED PARTNERSHIP AGREEMENT**

**OF**

**ENDO LP**

This Limited Partnership Agreement (the "**Agreement**") is made and entered into as of August 1, 2025 (the "**Effective Date**"), by and between ELP 2025 GP Limited, a company incorporated in Ireland with company registration number 793019 and its registered office at College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland (the "**General Partner**") and Mallinckrodt plc, a public limited company incorporated in Ireland with company registration number 522227 and its registered office at College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland (the "**Limited Partner**" and, together with the General Partner, the "**Partners**") of Endo LP (the "**Partnership**"), pursuant to the provisions of the Delaware Revised Uniform Limited Partnership Act (the "**Act**").

NOW, THEREFORE, in consideration of the mutual covenants and conditions herein, the parties hereto agree as follows:

**ARTICLE 1**

**NAME, PURPOSE AND OFFICES OF PARTNERSHIP**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.1 Name**. The name of the Partnership is Endo LP. The affairs of the Partnership shall be conducted under the Partnership name, or such other name as the General Partner may from time to time designate upon written notice to the Limited Partner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.2 Purposes**. The Partnership was formed for the object and purpose of, and the nature of the business to be conducted and promoted by the Partnership is, engaging in any lawful act or activity for which limited partnerships may be formed under the Act. The Partnership's purposes may be changed or expanded by the General Partner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.3 Principal Office**. The principal office of the Partnership shall be located at such place as the General Partner may from time to time designate. The General Partner shall provide each Limited Partner with prompt written notice of any change in the location of the Partnership's principal office.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.4 Registered Agent and Office**. The name of the registered agent for service of process of the Partnership and the address of the Partnership's registered office in the State of Delaware shall be such agent or office in the State of Delaware as the General Partner may from time to time designate.

**ARTICLE 2**

**TERM OF PARTNERSHIP; TERMINATION of PARTNERSHIP interests**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1 Term**. The term of the Partnership commenced upon the filing of the Certificate of Limited Partnership of the Partnership with the office of the Secretary of State of the State of Delaware and shall continue indefinitely, or until dissolution, termination, or liquidation of the Partnership in accordance with the Act and this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.2 Events Affecting a Limited Partner of the Partnership**. Except as otherwise provided by Section 9.1(c) and Section 9.1(e), the death, temporary or permanent incapacity, insanity, incompetency, Bankruptcy, liquidation, dissolution, reorganization, merger, sale of all or substantially all the partnership interests, stock or assets of, or other change in the ownership or nature of any Limited Partner shall not dissolve the Partnership.

**ARTICLE 3**

**PARTNERSHIP INTERESTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.1 Name and Address; Partnership Interests**. The names and addresses of each Partner and the amount of each Partner's capital contribution to the Partnership shall be kept in the Partnership's books and records.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.2 Additional Interests.** In the sole discretion of the General Partner, the Partnership may issue, sell or grant to any persons a partnership interest in the Partnership.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.3 Admission of Limited Partners**. A person may be admitted as a Limited Partner in the sole discretion of the General Partner.

**ARTICLE 4**

**CAPITAL ACCOUNTS AND CAPITAL CONTRIBUTIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.1 Capital Accounts**. An individual capital account shall be maintained for each Partner by the General Partner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.2 Capital Contributions of the Partners**. Each Partner's capital contributions (each, a "**Capital Contribution**") are as set forth in the books and records of the Partnership.

**ARTICLE 5**

**PARTNERSHIP ALLOCATIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.1 Allocation of Profit or Loss**. Except as otherwise determined to be appropriate by the General Partner, profit and loss of the Partnership shall be allocated among the Partners in proportion to their respective Capital Contributions.

**ARTICLE 6**

**WITHDRAWALS BY AND DISTRIBUTIONS TO THE PARTNERS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.1 Withdrawals by the Partners**. No Partner may withdraw any amount from its capital account without the prior written consent of the General Partner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.2 No Obligation to Repay or Restore**. Except as required by law or the terms of this Agreement, no Partner shall be obligated at any time to repay or restore to the Partnership all or any part of any distribution made to it from the Partnership.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.3 Distributions**. The General Partner shall make distributions of available cash from time to time in its discretion.

**ARTICLE 7**

**MANAGEMENT DUTIES AND RESTRICTIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.1 Management**. The General Partner shall have the sole and exclusive right to manage, control, and conduct the affairs of the Partnership, including the pledge of Partnership assets, opening of Partnership accounts, and to do any and all acts on behalf of the Partnership, including exercise of rights to elect to adjust the tax basis of Partnership assets and to revoke such elections and to make such other tax elections as the General Partner shall deem appropriate. The General Partner, in its sole discretion, may enter into a separate supplemental agreement with a Limited Partner and as such may agree to additional provisions. The General Partner has the power and authority to delegate to one or more other persons any or all of the General Partner's rights, powers and duties to manage and control the business and affairs of the Partnership.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.2 No Control by the Limited Partner**. The Limited Partner shall take no part in the control or management of the affairs of the Partnership nor shall the Limited Partner have any authority to act for or on behalf of the Partnership or to vote on any matter relative to the Partnership and its affairs except as specifically permitted by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.3 No Personal Liability of the Limited Partner**. Except as otherwise expressly provided in the Act, by applicable law, or expressly stated in this Agreement, the Limited Partner will not be obligated personally for any debt, obligation, or liability of the Partnership or another Partner, whether arising in contract, tort, or otherwise, solely by reason of being the Limited Partner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.4 Liability of the General Partner**. Except as otherwise expressly provided in the Act, by applicable law, or expressly stated in this Agreement, the General Partner will be obligated personally for any debt, obligation, or liability of the Partnership.

**ARTICLE 8**

**TRANSFER OF PARTNERSHIP INTERESTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.1 Transfer by Partners**. No Limited Partner shall sell, assign, pledge, mortgage, or otherwise dispose of or transfer its interest in the Partnership without the prior written unanimous consent of the General Partner.

**ARTICLE 9**

**DISSOLUTION AND LIQUIDATION OF THE PARTNERSHIP**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.1 Dissolution**. The Partnership shall be dissolved and its affairs wound up only upon the occurrence of any of the following events or times:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) An election to dissolve the Partnership made by the General Partner;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The sale, exchange, involuntary conversion, or other disposition or transfer of all or substantially all the assets of the Partnership;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) At any time there is no General Partner; provided ,that the Partnership shall not be dissolved if within ninety (90) days after the first date on which there is no General Partner, the Limited Partner shall have elected to continue the business of the Partnership and agreed to the appointment, effective as of the date of such election, of a successor General Partner

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) The entry of a decree of judicial dissolution under Section 17-802 of the Act; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) At any time there is no Limited Partner; provided ,that the Partnership shall not be dissolved if within ninety (90) days after the first date on which there is no Limited Partner, the General Partner shall have elected to continue the business of the Partnership and agreed to the admission, effective as of the date of such election, of a successor Limited Partner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.2 Winding up Procedures**. Promptly upon dissolution of the Partnership, the affairs of the Partnership shall be wound up and the Partnership liquidated.

**ARTICLE 10**

**FISCAL YEAR**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.1 Fiscal Year**. The Partnership's fiscal year shall be the calendar year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.2 Tax Classification**. The Partnership shall be treated as disregarded as separate from the Limited Partner for all U.S. federal (and applicable state and local) income tax purposes. The Limited Partner, the General Partner and each officer of the Partnership is authorized to make an election pursuant to Regulations Section 301.7701-3(c) in accordance with the intended tax classification.

**ARTICLE 11**

**INDEMNIFICATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11.1 Indemnification**. The Partnership shall indemnify, defend and hold harmless the Partners, officers, employees and agents of the Partnership (individually, an "**Indemnitee**") to the fullest extent permissible under Delaware law from and against any and all losses, claims, damages, liabilities, expenses (including legal fees and expenses), judgments, fines, settlements and other amounts arising from any and all claims, demands, actions, suits or proceedings, civil, criminal, administrative or investigative, in which the Indemnitee may be involved, or threatened to be involved, as a party or otherwise by reason of such Indemnitee's status as a partner, officer, employee or agent of the Partnership if (i) the Indemnitee acted in good faith and in a manner such Indemnitee believed to be in, or not opposed to, the best interests of the Partnership, and, with respect to any criminal proceeding, had no reasonable cause to believe such Indemnitee's conduct was unlawful, and (ii) the Indemnitee's conduct did not constitute gross negligence or willful or wanton misconduct. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere<u>,</u> or its equivalent, shall not, of itself, create a presumption that the Indemnitee acted in a manner contrary to that specified in (i) or (ii) above. Any indemnification pursuant to this <u>ARTICLE 11</u> shall be made only out of the assets of the Partnership and no Partner shall have any personal liability on account thereof. In the event that an amendment to this Agreement reduces or eliminates any Indemnitee<sup>'</sup>s right to indemnification pursuant to this <u>ARTICLE 11</u>, such amendment shall not be effective with respect to any Indemnitee's right to indemnification that accrued prior to the date of such amendment. For purposes of this <u>ARTICLE 11</u>, a right to indemnification shall accrue as of the date of the event underlying the claim that gives rise to such right to indemnification. All calculations of claims and the amount of indemnification to which any Indemnitee is entitled under this <u>ARTICLE 11</u> shall be made (i) giving effect to the tax consequences of any such claim and (ii) after deduction of all proceeds of insurance net of retroactive premiums and self-insurance retention recoverable by the Indemnitee with respect to such claims

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11.2 Expenses**. Expenses (including reasonable legal fees) incurred by an Indemnitee in defending any claim, demand, action, suit or proceeding described in the foregoing paragraph may, from time to time, be advanced by the Partnership prior to the final disposition of such claim, demand, action, suit or proceeding, in the discretion of the Partners, upon receipt by the Partnership of an undertaking by or on behalf of the Indemnitee to repay such amount if it shall be determined that the Indemnitee is not entitled to be indemnified as authorized in this <u>ARTICLE 11</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11.3 Not Exclusive**. The indemnification and advancement of expenses set forth in this <u>ARTICLE 11</u> shall not be exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any statute, the Partnership's certificate of limited partnership, this Agreement, any other agreement, a vote of the Partners, a policy of insurance or otherwise, and shall not limit in any way any right which the Partnership may have to make additional indemnifications with respect to the same or different persons or classes of persons, as determined by the Partners. The indemnification and advancement of expenses set forth in this <u>ARTICLE 11</u> shall continue as to each Indemnitee who has ceased to hold the position giving rise to such indemnification and shall inure to the benefit of the heirs, executors, administrators, successors and assigns of such a person or entity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11.4 Insurance.** The Partnership may purchase and maintain insurance on behalf of any Indemnitee against any liability asserted against an Indemnitee and incurred by an Indemnitee in such capacity, or arising out of such Indemnitee's status as aforesaid, whether or not the Partnership would have the power to indemnify such Indemnitee against such liability under this <u>ARTICLE 11</u>.

**ARTICLE 12**

**OTHER PROVISIONS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12.1 Governing Law**. This Agreement shall be governed by and construed under the laws of the State of Delaware as applied to agreements among the residents of such state made and to be performed entirely within such state, and without giving effect to the conflict of laws principles thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12.2 Execution and Filing of Documents**. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12.3 Binding Agreement**. This Agreement shall be binding upon the transferees, successors, assigns, and legal representatives of the Partners.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12.4 Amendment**. This Agreement may only be amended with the consent of the General Partner and the Limited Partner.

*[Remainder of page intentionally left blank. Signature page to follow.]*

IN WITNESS WHEREOF, the Partners have executed this Agreement as of the Effective Date.

---

| | |
|:---|:---|
| **GENERAL PARTNER:** | **GENERAL PARTNER:** |
| ELP 2025 GP LIMITED | ELP 2025 GP LIMITED |
| By: | /s/ Alasdair John Fenlon |
| Name: | Alasdair John Fenlon |
| Title: | Director |

---

IN WITNESS WHEREOF, the Partners have executed this Agreement as of the Effective Date.

---

| | |
|:---|:---|
| **LIMITED PARTNER:** | **LIMITED PARTNER:** |
| MALLINCKRODT PLC | MALLINCKRODT PLC |
| By: | /s/ Sigurdur Olafsson |
| Name: | Sigurdur Olafsson |
| Title: | Authorised Signatory |

---